Alithea Bio Receives German Innovation Award 2026 for HLA-Compass Platform

Alithea Biotechnology GmbH has been named a winner at the German Innovation Award 2026, recognised in the Excellence in Business to Business — Medical Technologies category for HLA-Compass, our AI-powered immunopeptidomics platform for safe immunotherapy development.

A milestone for precision immunotherapy

Alisa Fuchs, PhD, represented the Alithea Bio team at the award ceremony, accepting recognition that reflects years of intensive research and technological development. The German Design Council’s Innovation Award highlights innovations that deliver measurable added value — precisely the mission that drives HLA-Compass.

Why HLA-Compass is transforming cancer immunotherapy

Traditional oncology approaches are often reactive. HLA-Compass is changing that by giving BioPharma researchers and cancer vaccine developers access to the world’s most validated HLA-peptide database — enabling faster, safer, and more inclusive therapy development.

What HLA-Compass enables for researchers

Using deep-learning algorithms to predict HLA binding with unprecedented precision, HLA-Compass allows pharmaceutical companies and researchers to:

• Reduce toxicity — minimise off-target effects through comprehensive HLA binding prediction and off-target safety screening
• Increase speed — drastically shorten the journey from initial lab discovery to patient treatment
• Ensure inclusivity — develop therapies that work across an extensive range of HLA alleles and genetic backgrounds

Looking ahead

As our CEO Fanny Giannou emphasises, Alithea Bio is not just providing data — we are providing certainty. This award serves as a catalyst for our team to continue pushing the boundaries of what is possible in personalised medicine and neoantigen-based cancer vaccine development.

We are proud to be recognised alongside Germany’s most innovative companies and remain committed to accelerating the future of precision immunotherapy.